Nanomedicine for the Treatment of Rheumatoid Arthritis

Cited 5 time in webofscience Cited 0 time in scopus
  • Hit : 47
  • Download : 0
Rheumatoid arthritis (RA) is a chronic autoimmune disease that results in severe inflammatory microenvironments in the joint tissues. In clinics, disease-modifying antirheumatic drugs (DMARDs) are generally prescribed to patients with RA, but their long-term use often shows toxicity in some organs such as the gastrointestinal system, skin, and kidneys and immunosuppression-mediated infection. Nanomedicine has emerged as a new therapeutic strategy to efficiently localize the drugs in inflamed joints for the treatment of RA. In this Review, we introduce recent research in the area of nanomedicine for the treatment of RA and discuss how the nanomedicine can be used to deliver therapeutic agents to the inflamed joints and manage the progression of RA, particularly focusing on targeted delivery, controlled drug release, and immune modulation.
Publisher
AMER CHEMICAL SOC
Issue Date
2021-02
Language
English
Article Type
Review
Citation

MOLECULAR PHARMACEUTICS, v.18, no.2, pp.539 - 549

ISSN
1543-8384
DOI
10.1021/acs.molpharmaceut.0c00295
URI
http://hdl.handle.net/10203/285341
Appears in Collection
BiS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 5 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0